查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1805852

重組人促濾泡素市場報告：趨勢、預測和競爭分析（至 2031 年）

Recombinant Human Follitropin Market Report: Trends, Forecast and Competitive Analysis to 2031
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

全球重組人促濾泡素市場前景廣闊，在女性用和男性細分市場都存在機會。預計2025年至2031年期間，全球重組人促濾泡素市場的複合年成長率將達到5.4%。該市場的主要促進因素包括不孕症盛行率的上升、輔助生殖技術的普及以及生物相似藥的日益普及。

  • Lucintel 預測，150 IU 品種將在預測期內達到最高成長。
  • 從應用來看，女性用預計將實現高成長。
  • 依地區分類，預計亞太地區將在預測期內實現最高成長。

重組人促濾泡素市場的新趨勢

重組人促濾泡素產業蓬勃發展，受技術變革、醫療實踐發展和患者需求的驅動。許多關鍵趨勢正在塑造著現在和未來。

  • 生物相似藥需求不斷成長：隨著重組促促濾泡素原研藥專利到期，生物相似藥正進入市場。生物相似藥具有相似的療效和安全性，但價格可能更低，使患者更容易獲得治療，也更能負擔得起。人們對生物相似藥的評價日益積極，監管部門也紛紛核准，這可能會進一步加速其應用，並加劇市場價格競爭。
  • 個人化給藥方案的發展：根據患者特定因素（例如年齡、卵巢儲備指標以及先前刺激反應）客製化促促濾泡素治療方案和劑量的趨勢日益成長。個別化治療的目標是改善治療效果並降低卵巢過度刺激症候群的風險。針對個體化給藥的預測性生物標記和演算法的研究正在蓬勃發展。
  • 開發更便捷的給藥裝置：製藥公司正在致力於開發重組促促濾泡素的便捷給藥裝置，例如配備細針的預填充筆和自動注射系統。這些裝置旨在提高患者便利性，減少注射恐懼，並提高患者對治療方法的依從性。便捷的自我給藥方式可改善病患的整體體驗。
  • 長效促促濾泡素製劑日益受到關注：長效重組促促濾泡素製劑的開發和上市正日益受到關注。這些製劑的給藥頻率低於每日給藥製劑，從而可以提高患者的依從性並減輕治療負擔。臨床試驗正在評估長效製劑在不同患者族群的療效和安全性。
  • 拓展傳統體外受精 (IVF) 以外的應用：重組促促濾泡素主要用於體外受精 (IVF) 和其他輔助生殖技術，但我們正在探索其在更多生殖醫學領域的潛在應用，包括子宮內人工授精的促排卵以及某些激素失衡的治療。探索這些擴展的用途可能會提高重組促促濾泡素的市場滲透率。

這些即將到來的趨勢將改變重組人促卵泡激素市場，透過生物相似藥增加治療機會，透過個人化劑量最大化治療效果，透過新型輸送裝置和緩釋性提高患者便利性，探索新型治療應用，為患者友好且更具成本效益的促濾泡素市場鋪平道路。

重組人促濾泡素市場的最新趨勢

重組人促濾泡素市場持續成長，得益於旨在提高治療效果、安全性和患者舒適度的各項技術進步。這些技術進步涵蓋了產品生命週期的各個領域。

  • 新型生物相似藥上市：隨著早期重組促促濾泡素產品的專利到期，新型生物相似藥正在各市場陸續上市。這些生物相似藥經過廣泛測試，證明其品質、療效和安全性與原廠藥相似，為患者提供了經濟實惠的治療選擇，並增強了市場競爭。
  • 生產和純化製程改進：我們持續進行研發工作，致力於簡化重組促濾泡素的生產和純化製程。這些改進旨在提高產品品質、降低生產成本並確保供應穩定性，以滿足日益成長的全球需求。製程改進還能使產品純度更高、雜質更少。
  • 注射器的改進：藥廠正在不斷研發重組促促濾泡素藥物輸送技術。這些進展包括更便捷、更符合人體工學的預填充筆、更細的針頭（以減輕刺痛感）以及精準給藥系統（以提高患者依從性並減少因自行用藥造成的用藥錯誤）。
  • 藥物基因體學與個人化醫療：我們正在研究藥物基因體學在預測個別患者對重組促促濾泡素反應的潛在應用。識別卵巢刺激反應的基因標記，或可幫助臨床醫生量身定做治療方法和劑量，從而可能提高成功率並減少不良反應。
  • 新治療方法的臨床試驗：目前的臨床試驗正在評估使用重組促濾泡素的新治療方法，包括起始劑量、刺激持續時間以及與其他生育藥物聯合使用的變化。這些試驗旨在最佳化現有方案，為其他患者亞群確定更成功的治療方法，並最終提高輔助生殖技術的整體成功率。

重組人促濾泡素市場中的這些新興趨勢，包括新的生物學名藥的推出、製造和交付創新、對個性化醫療的關注以及正在進行的臨床研究，都在通過使治療更容易獲得、提高產品質量和患者便利性以及改善臨床結果來影響市場。

目錄

第1章執行摘要

第2章 市場概述

  • 背景和分類
  • 供應鏈

第3章：市場趨勢與預測分析

  • 宏觀經濟趨勢與預測
  • 產業驅動力與挑戰
  • PESTLE分析
  • 專利分析
  • 法規環境

4. 全球重組人促濾泡素市場（依類型）

  • 概述
  • 吸引力分析：依類型
  • 75IU：趨勢與預測（2019-2031）
  • 150IU：趨勢與預測（2019-2031）
  • 300IU：趨勢與預測（2019-2031）
  • 其他：趨勢與預測（2019-2031）

5. 全球重組人促濾泡素市場（依應用）

  • 概述
  • 吸引力分析：依用途
  • 女性用：趨勢與預測（2019-2031）
  • 男裝：趨勢與預測（2019-2031）

第6章區域分析

  • 概述
  • 全球重組促濾泡素市場（依地區）

7. 北美重組人促促濾泡素市場

  • 概述
  • 北美重組人促促濾泡素市場（依類型）
  • 北美重組人促促濾泡素市場（依應用）
  • 美國重組人促濾泡素市場
  • 墨西哥重組人促濾泡素市場
  • 加拿大重組人促濾泡素市場

8. 歐洲重組人促促濾泡素市場

  • 概述
  • 歐洲重組人促促濾泡素市場類型
  • 歐洲重組人促促濾泡素市場（依應用）
  • 德國重組人促濾泡素市場
  • 法國重組人促濾泡素市場
  • 西班牙重組人促濾泡素市場
  • 義大利重組人促濾泡素市場
  • 英國重組人促濾泡素市場

9. 亞太地區重組人類促濾泡素市場

  • 概述
  • 亞太地區重組促濾泡素市場（依類型）
  • 亞太地區重組促濾泡素市場（依應用）
  • 日本重組促濾泡素市場
  • 印度重組人促濾泡素市場
  • 中國重組促濾泡素市場
  • 韓國重組人促濾泡素市場
  • 印尼重組人促濾泡素市場

10. 其他地區（ROW）重組人促促濾泡素市場

  • 概述
  • 世界其他地區（ROW）重組人促促濾泡素市場（依類型）
  • 世界其他地區（ROW）重組人促促濾泡素市場（依應用）
  • 中東重組人促濾泡素市場
  • 南美洲重組人促促濾泡素市場
  • 非洲重組人促濾泡素市場

第11章 競爭分析

  • 產品系列分析
  • 營運整合
  • 波特五力分析
    • 競爭對手之間的競爭
    • 買方議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 新進入者的威脅
  • 市場佔有率分析

第12章機會與策略分析

  • 價值鏈分析
  • 成長機會分析
    • 依類型分類的成長機會
    • 成長機會：依應用
  • 全球重組人促濾泡素市場的新趨勢
  • 戰略分析
    • 新產品開發
    • 認證和許可
    • 企業合併（M&A）、協議、合作與合資企業

第13章 價值鏈主要企業概況

  • 競爭分析
  • Merck
  • Organon
  • Gedeon Richter
  • Ferring
  • Changchun High-Tech
  • Theramex
  • Qilu Pharmaceutical

第14章 附錄

  • 圖片列表
  • 表格列表
  • 分析方法
  • 免責聲明
  • 版權
  • 簡稱和技術單位
  • 關於 Lucintel
  • 詢問

The future of the global recombinant human follitropin market looks promising with opportunities in the women and men markets. The global recombinant human follitropin market is expected to grow with a CAGR of 5.4% from 2025 to 2031. The major drivers for this market are the increasing prevalence of infertility, the rising adoption of assisted reproductive technologies, and the growing availability of biosimilar treatments.

  • Lucintel forecasts that, within the type category, 150IU is expected to witness the highest growth over the forecast period.
  • Within the application category, women are expected to witness higher growth.
  • In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Recombinant Human Follitropin Market

The recombinant human follitropin industry is dynamic and is driven by changes in technology, evolving medical practices, and patient requirements. A number of key trends are shaping its present and future.

  • Growing Demand for Biosimilars: As patents on original recombinant follitropin products expire, biosimilar versions are entering the market. The biosimilars have similar efficacy and safety profiles at potentially lower prices, making treatment more accessible and affordable to patients. The increasing favor and regulatory approvals for biosimilars are likely to further accelerate their adoption, fostering more price competition in the marketplace.
  • Developments in Individualized Dosing Regimens: Increasingly, there is a move towards customizing follitropin treatment protocols and dosing according to patient-specific factors, including age, markers for ovarian reserve, and prior response to stimulation. The goal of individualized therapy is to enhance therapeutic outcomes and reduce the risk of ovarian hyperstimulation syndrome. Investigation into predictive biomarkers and algorithmic studies for individualized dosing is in full swing.
  • Creation of More Convenient Delivery Devices: Pharmaceutical firms are working on creating convenient delivery devices for recombinant follitropin, including prefilled pens with thin needles and automatic injection systems. These devices are designed to enhance patient convenience, minimize injection fear, and increase compliance with treatment regimens. Ease of self-administration leads to an improved overall patient experience.
  • Increasing Interest in Long-Acting Follitropin Preparations: The creation and launch of long-acting recombinant follitropin preparations are increasing in popularity. These preparations involve less frequent administration than daily preparations, which could enhance patient compliance and decrease the treatment burden. Clinical trials are assessing the efficacy and safety of longer-acting formulations across different patient populations.
  • Increasing Uses Beyond Conventional IVF: Though predominantly employed in in vitro fertilization and other assisted reproductive technologies, the study is investigating the possible uses of recombinant follitropin in more fields of reproductive health, including ovulation induction for intrauterine insemination and treatment of some hormonal imbalances. The exploration of these expanded uses may increase the market penetration of recombinant follitropin.

These upcoming trends are combined to transform the recombinant human follitropin market by enhancing the accessibility of treatments through biosimilars, maximizing treatment efficiency through individualized dosing, improving patient convenience with new delivery devices and extended-release formulations, and seeking novel therapeutic uses. These trends look towards a patient-friendly and more cost-efficient future market.

Recent Developments in the Recombinant Human Follitropin Market

The recombinant human follitropin market continues to grow with advances aimed at enhancing treatment effectiveness, safety, and patient comfort. These developments cover different areas of the product life cycle.

  • Launch of New Biosimilar Formulations: Patent expirations for a number of initial recombinant follitropin products have resulted in the launch of new biosimilar formulations in various markets. These biosimilars are tested extensively to prove similar quality, efficacy, and safety to the originator products, providing cheaper treatment alternatives for patients and enhancing competition in the market.
  • Improvements in Manufacturing and Purification Processes: Continued research and development activities are directed towards streamlining the manufacturing and purification processes of recombinant follitropin. Such improvements are intended to improve product quality, lower the costs of production, and provide a consistent supply to fulfill the increasing global demand. Better processes can also result in products that are higher in purity and possibly lower in impurities.
  • Improved Injection Device Development: Pharmaceutical manufacturers are constantly developing advances in drug delivery technology in the form of recombinant follitropin. Some of these developments include more convenient prefilled pens that have improved ergonomics, thinner needles to reduce stinging, and precise dosing systems to enhance patient compliance and decrease drug errors with self-administration.
  • Pharmacogenomics and Personalized Medicine: Research is investigating the possibility of using pharmacogenomics to anticipate response to recombinant follitropin in individual patients. The identification of genetic markers of response to ovarian stimulation could allow clinicians to tailor treatment regimens, doses, and even enhance success rates and reduce unwanted effects.
  • Clinical Trials for New Treatment Regimens: Current clinical trials are evaluating new treatment regimens with recombinant follitropin, such as varying the dose of initiation, duration of stimulation, and combination with other fertility drugs. These trials seek to optimize existing protocols and determine more successful approaches for other patient subgroups, ultimately leading to overall enhanced success with assisted reproductive technology.

These new trends in the recombinant human follitropin market, such as the launch of new biosimilars, innovation in manufacturing and delivery, emphasis on personalized medicine, and continued clinical studies, are all influencing the market by making treatment more accessible, enhancing product quality and patient ease, and reaching for improved clinical outcomes.

Strategic Growth Opportunities in the Recombinant Human Follitropin Market

The recombinant human follitropin market presents several strategic growth opportunities across its primary application in assisted reproductive technologies and related infertility treatments.

  • Increasing Access in Underserved Geographies: A key area of opportunity for growth is increasing access to recombinant follitropin in emerging markets and underserved territories with limited access to cutting-edge fertility treatment due to cost and infrastructure. Building partnerships with in-country healthcare providers and instituting tiered pricing practices can help gain traction in these markets and serve the unmet need of a large population of patients.
  • Growing Adoption in Intrauterine Insemination (IUI): Though predominantly applied with IVF, recombinant follitropin can also be used to increase the success of IUI by stimulating the growth of several mature follicles. Strategic initiatives to make fertility experts aware of recombinant follitropin's advantages when included in IUI treatment protocols and to increase its availability for this purpose can fuel market growth in this segment.
  • Personalizing Controlled Ovarian Stimulation Regimens for Individual Patient Profiles: Customization of COS regimens with recombinant follitropin on the basis of patient-specific characteristics, including age, BMI, AMH level, and past ART history, presents a major potential to maximize success rates and minimize side effects. Establishing and marketing evidence-based individualized stimulation protocols can further maximize the value proposition of recombinant follitropin.
  • Taking Advantage of Fertility Tourism Growth: The growing phenomenon of fertility tourism, where patients go abroad for lower-cost or specialty fertility care, offers an opportunity for growth for clinics and vendors in destination countries. Having high-quality recombinant follitropin and standardized treatment protocols available in these facilities can bring more overseas patients.
  • Investigating Co-marketing and Combination Therapies: Cooperating with firms providing complementary fertility treatments or formulating combination therapies that include recombinant follitropin with other gonadotropins or adjunctive therapies can open new avenues for growth. Establishing the synergistic value of such combinations through clinical studies can improve therapy effectiveness and expand the recombinant follitropin market.

These strategic growth prospects, including geographical expansion, wider usage in ART, individualized treatment strategies, utilization of fertility tourism, and examining combination therapies, have the capability to take the recombinant human follitropin market by storm by targeting more patients and maximizing treatment outcomes.

Recombinant Human Follitropin Market Driver and Challenges

The recombinant human follitropin market is influenced by a myriad of drivers and challenges, including technological innovation, economic considerations, and the regulatory environment. It is essential for stakeholders in this industry to understand these influences.

The factors responsible for driving the recombinant human follitropin market include:

1. Rising Incidence of Infertility: The global prevalence of infertility is increasing due to various factors, including lifestyle changes, environmental pollution, and delaying childbearing. This growing need for effective fertility treatments, where recombinant follitropin plays a crucial role in ovarian stimulation, is a primary driver of market growth.

2. Technology Advances in Assisted Reproductive Technologies (ART): Unceasing innovations in ART processes, including IVF and ICSI, have made them very successful and in greater demand. Recombinant follitropin is the building block technology behind these procedures, making it increasingly in demand in tandem with the growth of the ART market.

3. Expanding Awareness and Acceptance of Fertility Treatment: As society becomes more aware of infertility as a health issue and less stigmatized about seeking treatment, more people and couples are turning to fertility interventions. That expanded acceptance means a greater pool of patients for recombinant follitropin.

4. Recombinant Superiority Over Urinary-Derived Products: Recombinant human follitropin has more purity, batch-to-batch consistency, and a lower viral contamination risk than traditional urinary-derived FSH. Its benefits have resulted in its popularity as the product of choice for ovarian stimulation, driving market growth.

5. Increasing Healthcare Spending in Developing Economies: As developing economies witness growth in healthcare spending and infrastructure, access to sophisticated fertility treatments, such as recombinant follitropin, is becoming better. This greater affordability and availability in erstwhile underserved markets are major drivers of market growth.

Challenges in the recombinant human follitropin market are:

1. High Cost of Treatment: The total cost of ART cycles, including the expense of recombinant follitropin medications, can be prohibitive to many couples. This is a high cost that can pose a financial hurdle to receiving the treatment, especially in areas with meager insurance coverage or public funds for fertility treatment.

2. Strict Regulatory Approvals: The creation and marketing of recombinant biologics such as follitropin are subjected to rigorous regulatory review in a process that protects safety and efficacy. This challenging and sometimes lengthy set of approval processes can be challenging for manufacturers, potentially slowing the entry into the market and raising costs of development.

3. Risk of Ovarian Hyperstimulation Syndrome: Although recombinant follitropin is safe in general, the possibility of ovarian hyperstimulation syndrome, a potentially severe complication of ovarian stimulation, poses a continued concern. Clinicians have to monitor patients carefully and modify treatment protocols to avoid this risk, which can impact prescribing behaviors.

In summary, the recombinant human follitropin market is fueled mainly by the rising incidence of infertility, innovative progress in ART, rising awareness about treatment, and the benefits of recombinant technology. But challenges such as the issue of high treatment cost, strict regulatory demands, and the risk of OHSS must be countered to promote easier access and safer use of these critical drugs.

List of Recombinant Human Follitropin Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies, recombinant human follitropin companies cater to increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the recombinant human follitropin companies profiled in this report include:

  • Merck
  • Organon
  • Gedeon Richter
  • Ferring
  • Changchun High-Tech
  • Theramex
  • Qilu Pharmaceutical

Recombinant Human Follitropin Market by Segment

The study includes a forecast for the global recombinant human follitropin market by type, application, and region.

Recombinant Human Follitropin Market by Type [Value from 2019 to 2031]:

  • 75IU
  • 150IU
  • 300IU
  • Others

Recombinant Human Follitropin Market by Application [Value from 2019 to 2031]:

  • Women
  • Men

Recombinant Human Follitropin Market by Region [Value from 2019 to 2031]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Recombinant Human Follitropin Market

Current trends in the recombinant human follitropin market follow wider trends for infertility therapy across the world. Recombinant human follitropin, which is a highly purified follicle-stimulating hormone, has benefits regarding consistency and lower immunogenicity over the previously used older, urinary-derived compounds. The rise in infertility incidence, together with advances in assisted reproductive technologies, is driving market growth in major geographic regions. Regulatory environments, the advent of biosimilars, and increased interest in personalized medicine are all helping drive the changing dynamics of this market. This primer sets a context for discussing particular developments in the United States, China, Germany, India, and Japan.

  • United States: The US market for recombinant human follitropin is marked by high rates of adoption of assisted reproductive technologies and a strong focus on advanced treatments. Recent events include ongoing efforts to maximize stimulation protocols toward individualized patient outcomes. In addition, the market is seeing growing debates regarding the cost-effectiveness of various follitropin products and the resultant effects of future biosimilar introductions. Patient advocacy groups are also involved in influencing treatment guidelines and access to care.
  • China: The recombinant human follitropin market in China is growing at a very fast rate, with increased awareness of infertility and increased availability of assisted reproductive technologies. The latest events in the market involve the approval and launch of locally manufactured recombinant follitropin to make the product more affordable and available. Developing family planning policies of the government are also adding to the increased potential pool of patients. There is an increasing focus on quality and safety standards of locally produced biologics.
  • Germany: Germany's mature recombinant human follitropin market has a high concentration of established pharmaceutical firms and growing biosimilar product adoption. Recent trends have been price competition arising from the presence of biosimilars, impacting the cost of treatment. Emphasis is on providing high-quality patient care and improving treatment regimens within the context of an established health system. Improved formulations and delivery systems are still being researched.
  • India: The Indian market for recombinant human follitropin is growing with an increasing number of infertility clinics and awareness of treatments available. New developments include the increased availability of both imported and locally produced recombinant follitropin. Plans are being made to make these treatments available at a lower cost and to a wider portion of the population. Regulatory routes for biosimilars are also being shaped, potentially resulting in more affordable alternatives in the future.
  • Japan: The Japanese recombinant human follitropin market has experienced a steady rise in use, corresponding to increasing demand for infertility treatment. Recent trends include user-friendly injectors and patient convenience and comfort. While the willingness to adopt new therapy is conservative, the expanding social acceptability of assisted reproductive technologies is driving market expansion. Market access remains influenced by regulatory factors particular to the Japanese healthcare system.

Features of the Global Recombinant Human Follitropin Market

  • Market Size Estimates: Recombinant human follitropin market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
  • Segmentation Analysis: Recombinant human follitropin market size by type, application, and region in terms of value ($B).
  • Regional Analysis: Recombinant human follitropin market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the recombinant human follitropin market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the recombinant human follitropin market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the recombinant human follitropin market by type (75IU, 150IU, 300IU, and others), application (women and men), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.1 Macroeconomic Trends and Forecasts
  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Recombinant Human Follitropin Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 75IU: Trends and Forecast (2019-2031)
  • 4.4 150IU: Trends and Forecast (2019-2031)
  • 4.5 300IU: Trends and Forecast (2019-2031)
  • 4.6 Others: Trends and Forecast (2019-2031)

5. Global Recombinant Human Follitropin Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 Women: Trends and Forecast (2019-2031)
  • 5.4 Men: Trends and Forecast (2019-2031)

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global Recombinant Human Follitropin Market by Region

7. North American Recombinant Human Follitropin Market

  • 7.1 Overview
  • 7.2 North American Recombinant Human Follitropin Market by Type
  • 7.3 North American Recombinant Human Follitropin Market by Application
  • 7.4 United States Recombinant Human Follitropin Market
  • 7.5 Mexican Recombinant Human Follitropin Market
  • 7.6 Canadian Recombinant Human Follitropin Market

8. European Recombinant Human Follitropin Market

  • 8.1 Overview
  • 8.2 European Recombinant Human Follitropin Market by Type
  • 8.3 European Recombinant Human Follitropin Market by Application
  • 8.4 German Recombinant Human Follitropin Market
  • 8.5 French Recombinant Human Follitropin Market
  • 8.6 Spanish Recombinant Human Follitropin Market
  • 8.7 Italian Recombinant Human Follitropin Market
  • 8.8 United Kingdom Recombinant Human Follitropin Market

9. APAC Recombinant Human Follitropin Market

  • 9.1 Overview
  • 9.2 APAC Recombinant Human Follitropin Market by Type
  • 9.3 APAC Recombinant Human Follitropin Market by Application
  • 9.4 Japanese Recombinant Human Follitropin Market
  • 9.5 Indian Recombinant Human Follitropin Market
  • 9.6 Chinese Recombinant Human Follitropin Market
  • 9.7 South Korean Recombinant Human Follitropin Market
  • 9.8 Indonesian Recombinant Human Follitropin Market

10. ROW Recombinant Human Follitropin Market

  • 10.1 Overview
  • 10.2 ROW Recombinant Human Follitropin Market by Type
  • 10.3 ROW Recombinant Human Follitropin Market by Application
  • 10.4 Middle Eastern Recombinant Human Follitropin Market
  • 10.5 South American Recombinant Human Follitropin Market
  • 10.6 African Recombinant Human Follitropin Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunities by Type
    • 12.2.2 Growth Opportunities by Application
  • 12.3 Emerging Trends in the Global Recombinant Human Follitropin Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis
  • 13.2 Merck
    • Company Overview
    • Recombinant Human Follitropin Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 Organon
    • Company Overview
    • Recombinant Human Follitropin Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Gedeon Richter
    • Company Overview
    • Recombinant Human Follitropin Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 Ferring
    • Company Overview
    • Recombinant Human Follitropin Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 Changchun High-Tech
    • Company Overview
    • Recombinant Human Follitropin Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.7 Theramex
    • Company Overview
    • Recombinant Human Follitropin Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.8 Qilu Pharmaceutical
    • Company Overview
    • Recombinant Human Follitropin Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global Recombinant Human Follitropin Market
  • Figure 2.1: Usage of Recombinant Human Follitropin Market
  • Figure 2.2: Classification of the Global Recombinant Human Follitropin Market
  • Figure 2.3: Supply Chain of the Global Recombinant Human Follitropin Market
  • Figure 2.4: Driver and Challenges of the Recombinant Human Follitropin Market
  • Figure 3.1: Trends of the Global GDP Growth Rate
  • Figure 3.2: Trends of the Global Population Growth Rate
  • Figure 3.3: Trends of the Global Inflation Rate
  • Figure 3.4: Trends of the Global Unemployment Rate
  • Figure 3.5: Trends of the Regional GDP Growth Rate
  • Figure 3.6: Trends of the Regional Population Growth Rate
  • Figure 3.7: Trends of the Regional Inflation Rate
  • Figure 3.8: Trends of the Regional Unemployment Rate
  • Figure 3.9: Trends of Regional Per Capita Income
  • Figure 3.10: Forecast for the Global GDP Growth Rate
  • Figure 3.11: Forecast for the Global Population Growth Rate
  • Figure 3.12: Forecast for the Global Inflation Rate
  • Figure 3.13: Forecast for the Global Unemployment Rate
  • Figure 3.14: Forecast for the Regional GDP Growth Rate
  • Figure 3.15: Forecast for the Regional Population Growth Rate
  • Figure 3.16: Forecast for the Regional Inflation Rate
  • Figure 3.17: Forecast for the Regional Unemployment Rate
  • Figure 3.18: Forecast for Regional Per Capita Income
  • Figure 4.1: Global Recombinant Human Follitropin Market by Type in 2019, 2024, and 2031
  • Figure 4.2: Trends of the Global Recombinant Human Follitropin Market ($B) by Type
  • Figure 4.3: Forecast for the Global Recombinant Human Follitropin Market ($B) by Type
  • Figure 4.4: Trends and Forecast for 75IU in the Global Recombinant Human Follitropin Market (2019-2031)
  • Figure 4.5: Trends and Forecast for 150IU in the Global Recombinant Human Follitropin Market (2019-2031)
  • Figure 4.6: Trends and Forecast for 300IU in the Global Recombinant Human Follitropin Market (2019-2031)
  • Figure 4.7: Trends and Forecast for Others in the Global Recombinant Human Follitropin Market (2019-2031)
  • Figure 5.1: Global Recombinant Human Follitropin Market by Application in 2019, 2024, and 2031
  • Figure 5.2: Trends of the Global Recombinant Human Follitropin Market ($B) by Application
  • Figure 5.3: Forecast for the Global Recombinant Human Follitropin Market ($B) by Application
  • Figure 5.4: Trends and Forecast for Women in the Global Recombinant Human Follitropin Market (2019-2031)
  • Figure 5.5: Trends and Forecast for Men in the Global Recombinant Human Follitropin Market (2019-2031)
  • Figure 6.1: Trends of the Global Recombinant Human Follitropin Market ($B) by Region (2019-2024)
  • Figure 6.2: Forecast for the Global Recombinant Human Follitropin Market ($B) by Region (2025-2031)
  • Figure 7.1: Trends and Forecast for the North American Recombinant Human Follitropin Market (2019-2031)
  • Figure 7.2: North American Recombinant Human Follitropin Market by Type in 2019, 2024, and 2031
  • Figure 7.3: Trends of the North American Recombinant Human Follitropin Market ($B) by Type (2019-2024)
  • Figure 7.4: Forecast for the North American Recombinant Human Follitropin Market ($B) by Type (2025-2031)
  • Figure 7.5: North American Recombinant Human Follitropin Market by Application in 2019, 2024, and 2031
  • Figure 7.6: Trends of the North American Recombinant Human Follitropin Market ($B) by Application (2019-2024)
  • Figure 7.7: Forecast for the North American Recombinant Human Follitropin Market ($B) by Application (2025-2031)
  • Figure 7.8: Trends and Forecast for the United States Recombinant Human Follitropin Market ($B) (2019-2031)
  • Figure 7.9: Trends and Forecast for the Mexican Recombinant Human Follitropin Market ($B) (2019-2031)
  • Figure 7.10: Trends and Forecast for the Canadian Recombinant Human Follitropin Market ($B) (2019-2031)
  • Figure 8.1: Trends and Forecast for the European Recombinant Human Follitropin Market (2019-2031)
  • Figure 8.2: European Recombinant Human Follitropin Market by Type in 2019, 2024, and 2031
  • Figure 8.3: Trends of the European Recombinant Human Follitropin Market ($B) by Type (2019-2024)
  • Figure 8.4: Forecast for the European Recombinant Human Follitropin Market ($B) by Type (2025-2031)
  • Figure 8.5: European Recombinant Human Follitropin Market by Application in 2019, 2024, and 2031
  • Figure 8.6: Trends of the European Recombinant Human Follitropin Market ($B) by Application (2019-2024)
  • Figure 8.7: Forecast for the European Recombinant Human Follitropin Market ($B) by Application (2025-2031)
  • Figure 8.8: Trends and Forecast for the German Recombinant Human Follitropin Market ($B) (2019-2031)
  • Figure 8.9: Trends and Forecast for the French Recombinant Human Follitropin Market ($B) (2019-2031)
  • Figure 8.10: Trends and Forecast for the Spanish Recombinant Human Follitropin Market ($B) (2019-2031)
  • Figure 8.11: Trends and Forecast for the Italian Recombinant Human Follitropin Market ($B) (2019-2031)
  • Figure 8.12: Trends and Forecast for the United Kingdom Recombinant Human Follitropin Market ($B) (2019-2031)
  • Figure 9.1: Trends and Forecast for the APAC Recombinant Human Follitropin Market (2019-2031)
  • Figure 9.2: APAC Recombinant Human Follitropin Market by Type in 2019, 2024, and 2031
  • Figure 9.3: Trends of the APAC Recombinant Human Follitropin Market ($B) by Type (2019-2024)
  • Figure 9.4: Forecast for the APAC Recombinant Human Follitropin Market ($B) by Type (2025-2031)
  • Figure 9.5: APAC Recombinant Human Follitropin Market by Application in 2019, 2024, and 2031
  • Figure 9.6: Trends of the APAC Recombinant Human Follitropin Market ($B) by Application (2019-2024)
  • Figure 9.7: Forecast for the APAC Recombinant Human Follitropin Market ($B) by Application (2025-2031)
  • Figure 9.8: Trends and Forecast for the Japanese Recombinant Human Follitropin Market ($B) (2019-2031)
  • Figure 9.9: Trends and Forecast for the Indian Recombinant Human Follitropin Market ($B) (2019-2031)
  • Figure 9.10: Trends and Forecast for the Chinese Recombinant Human Follitropin Market ($B) (2019-2031)
  • Figure 9.11: Trends and Forecast for the South Korean Recombinant Human Follitropin Market ($B) (2019-2031)
  • Figure 9.12: Trends and Forecast for the Indonesian Recombinant Human Follitropin Market ($B) (2019-2031)
  • Figure 10.1: Trends and Forecast for the ROW Recombinant Human Follitropin Market (2019-2031)
  • Figure 10.2: ROW Recombinant Human Follitropin Market by Type in 2019, 2024, and 2031
  • Figure 10.3: Trends of the ROW Recombinant Human Follitropin Market ($B) by Type (2019-2024)
  • Figure 10.4: Forecast for the ROW Recombinant Human Follitropin Market ($B) by Type (2025-2031)
  • Figure 10.5: ROW Recombinant Human Follitropin Market by Application in 2019, 2024, and 2031
  • Figure 10.6: Trends of the ROW Recombinant Human Follitropin Market ($B) by Application (2019-2024)
  • Figure 10.7: Forecast for the ROW Recombinant Human Follitropin Market ($B) by Application (2025-2031)
  • Figure 10.8: Trends and Forecast for the Middle Eastern Recombinant Human Follitropin Market ($B) (2019-2031)
  • Figure 10.9: Trends and Forecast for the South American Recombinant Human Follitropin Market ($B) (2019-2031)
  • Figure 10.10: Trends and Forecast for the African Recombinant Human Follitropin Market ($B) (2019-2031)
  • Figure 11.1: Porter's Five Forces Analysis of the Global Recombinant Human Follitropin Market
  • Figure 11.2: Market Share (%) of Top Players in the Global Recombinant Human Follitropin Market (2024)
  • Figure 12.1: Growth Opportunities for the Global Recombinant Human Follitropin Market by Type
  • Figure 12.2: Growth Opportunities for the Global Recombinant Human Follitropin Market by Application
  • Figure 12.3: Growth Opportunities for the Global Recombinant Human Follitropin Market by Region
  • Figure 12.4: Emerging Trends in the Global Recombinant Human Follitropin Market

List of Tables

  • Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Recombinant Human Follitropin Market by Type and Application
  • Table 1.2: Attractiveness Analysis for the Recombinant Human Follitropin Market by Region
  • Table 1.3: Global Recombinant Human Follitropin Market Parameters and Attributes
  • Table 3.1: Trends of the Global Recombinant Human Follitropin Market (2019-2024)
  • Table 3.2: Forecast for the Global Recombinant Human Follitropin Market (2025-2031)
  • Table 4.1: Attractiveness Analysis for the Global Recombinant Human Follitropin Market by Type
  • Table 4.2: Market Size and CAGR of Various Type in the Global Recombinant Human Follitropin Market (2019-2024)
  • Table 4.3: Market Size and CAGR of Various Type in the Global Recombinant Human Follitropin Market (2025-2031)
  • Table 4.4: Trends of 75IU in the Global Recombinant Human Follitropin Market (2019-2024)
  • Table 4.5: Forecast for 75IU in the Global Recombinant Human Follitropin Market (2025-2031)
  • Table 4.6: Trends of 150IU in the Global Recombinant Human Follitropin Market (2019-2024)
  • Table 4.7: Forecast for 150IU in the Global Recombinant Human Follitropin Market (2025-2031)
  • Table 4.8: Trends of 300IU in the Global Recombinant Human Follitropin Market (2019-2024)
  • Table 4.9: Forecast for 300IU in the Global Recombinant Human Follitropin Market (2025-2031)
  • Table 4.10: Trends of Others in the Global Recombinant Human Follitropin Market (2019-2024)
  • Table 4.11: Forecast for Others in the Global Recombinant Human Follitropin Market (2025-2031)
  • Table 5.1: Attractiveness Analysis for the Global Recombinant Human Follitropin Market by Application
  • Table 5.2: Market Size and CAGR of Various Application in the Global Recombinant Human Follitropin Market (2019-2024)
  • Table 5.3: Market Size and CAGR of Various Application in the Global Recombinant Human Follitropin Market (2025-2031)
  • Table 5.4: Trends of Women in the Global Recombinant Human Follitropin Market (2019-2024)
  • Table 5.5: Forecast for Women in the Global Recombinant Human Follitropin Market (2025-2031)
  • Table 5.6: Trends of Men in the Global Recombinant Human Follitropin Market (2019-2024)
  • Table 5.7: Forecast for Men in the Global Recombinant Human Follitropin Market (2025-2031)
  • Table 6.1: Market Size and CAGR of Various Regions in the Global Recombinant Human Follitropin Market (2019-2024)
  • Table 6.2: Market Size and CAGR of Various Regions in the Global Recombinant Human Follitropin Market (2025-2031)
  • Table 7.1: Trends of the North American Recombinant Human Follitropin Market (2019-2024)
  • Table 7.2: Forecast for the North American Recombinant Human Follitropin Market (2025-2031)
  • Table 7.3: Market Size and CAGR of Various Type in the North American Recombinant Human Follitropin Market (2019-2024)
  • Table 7.4: Market Size and CAGR of Various Type in the North American Recombinant Human Follitropin Market (2025-2031)
  • Table 7.5: Market Size and CAGR of Various Application in the North American Recombinant Human Follitropin Market (2019-2024)
  • Table 7.6: Market Size and CAGR of Various Application in the North American Recombinant Human Follitropin Market (2025-2031)
  • Table 7.7: Trends and Forecast for the United States Recombinant Human Follitropin Market (2019-2031)
  • Table 7.8: Trends and Forecast for the Mexican Recombinant Human Follitropin Market (2019-2031)
  • Table 7.9: Trends and Forecast for the Canadian Recombinant Human Follitropin Market (2019-2031)
  • Table 8.1: Trends of the European Recombinant Human Follitropin Market (2019-2024)
  • Table 8.2: Forecast for the European Recombinant Human Follitropin Market (2025-2031)
  • Table 8.3: Market Size and CAGR of Various Type in the European Recombinant Human Follitropin Market (2019-2024)
  • Table 8.4: Market Size and CAGR of Various Type in the European Recombinant Human Follitropin Market (2025-2031)
  • Table 8.5: Market Size and CAGR of Various Application in the European Recombinant Human Follitropin Market (2019-2024)
  • Table 8.6: Market Size and CAGR of Various Application in the European Recombinant Human Follitropin Market (2025-2031)
  • Table 8.7: Trends and Forecast for the German Recombinant Human Follitropin Market (2019-2031)
  • Table 8.8: Trends and Forecast for the French Recombinant Human Follitropin Market (2019-2031)
  • Table 8.9: Trends and Forecast for the Spanish Recombinant Human Follitropin Market (2019-2031)
  • Table 8.10: Trends and Forecast for the Italian Recombinant Human Follitropin Market (2019-2031)
  • Table 8.11: Trends and Forecast for the United Kingdom Recombinant Human Follitropin Market (2019-2031)
  • Table 9.1: Trends of the APAC Recombinant Human Follitropin Market (2019-2024)
  • Table 9.2: Forecast for the APAC Recombinant Human Follitropin Market (2025-2031)
  • Table 9.3: Market Size and CAGR of Various Type in the APAC Recombinant Human Follitropin Market (2019-2024)
  • Table 9.4: Market Size and CAGR of Various Type in the APAC Recombinant Human Follitropin Market (2025-2031)
  • Table 9.5: Market Size and CAGR of Various Application in the APAC Recombinant Human Follitropin Market (2019-2024)
  • Table 9.6: Market Size and CAGR of Various Application in the APAC Recombinant Human Follitropin Market (2025-2031)
  • Table 9.7: Trends and Forecast for the Japanese Recombinant Human Follitropin Market (2019-2031)
  • Table 9.8: Trends and Forecast for the Indian Recombinant Human Follitropin Market (2019-2031)
  • Table 9.9: Trends and Forecast for the Chinese Recombinant Human Follitropin Market (2019-2031)
  • Table 9.10: Trends and Forecast for the South Korean Recombinant Human Follitropin Market (2019-2031)
  • Table 9.11: Trends and Forecast for the Indonesian Recombinant Human Follitropin Market (2019-2031)
  • Table 10.1: Trends of the ROW Recombinant Human Follitropin Market (2019-2024)
  • Table 10.2: Forecast for the ROW Recombinant Human Follitropin Market (2025-2031)
  • Table 10.3: Market Size and CAGR of Various Type in the ROW Recombinant Human Follitropin Market (2019-2024)
  • Table 10.4: Market Size and CAGR of Various Type in the ROW Recombinant Human Follitropin Market (2025-2031)
  • Table 10.5: Market Size and CAGR of Various Application in the ROW Recombinant Human Follitropin Market (2019-2024)
  • Table 10.6: Market Size and CAGR of Various Application in the ROW Recombinant Human Follitropin Market (2025-2031)
  • Table 10.7: Trends and Forecast for the Middle Eastern Recombinant Human Follitropin Market (2019-2031)
  • Table 10.8: Trends and Forecast for the South American Recombinant Human Follitropin Market (2019-2031)
  • Table 10.9: Trends and Forecast for the African Recombinant Human Follitropin Market (2019-2031)
  • Table 11.1: Product Mapping of Recombinant Human Follitropin Suppliers Based on Segments
  • Table 11.2: Operational Integration of Recombinant Human Follitropin Manufacturers
  • Table 11.3: Rankings of Suppliers Based on Recombinant Human Follitropin Revenue
  • Table 12.1: New Product Launches by Major Recombinant Human Follitropin Producers (2019-2024)
  • Table 12.2: Certification Acquired by Major Competitor in the Global Recombinant Human Follitropin Market